Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Gilead Sciences, Jazz Pharmaceuticals, Inc., and Sanofi Genzyme.

Cancer Summaries and Commentaries™ Update from Madrid on the Treatment of Breast Cancer, Lung Cancer, and Genitourinary Malignancies

Release Date: February 16, 2021
Expiration Date: February 16, 2022

Activity Overview

This online activity is designed to update oncologists on data presented in 2020 on emerging treatment options in breast, genitourinary, and lung cancer. This Cancer Summaries and Commentaries facilitates the critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 6 reports in the management of breast, genitourinary, and lung cancer. For each report, a text-based summary of the background, study design, key results, and conclusions is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Jazz Pharmaceuticals, Inc., and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe clinical study designs from recently reported and ongoing trials evaluating novel strategies for the management of patients with breast cancer, lung cancer, and genitourinary malignancies
  • Detail results from recent practice-changing clinical trials that evaluated novel strategies for the treatment of breast cancer, lung cancer, and genitourinary malignancies
  • Place recent evidence into the context of evolving treatment paradigms for the care of patients with breast cancer, lung cancer, and genitourinary malignancies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Aditya Bardia, MD, MPH
Aditya Bardia, MD, MPH
Attending Physician Dept of Medical Oncology
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: To institution: Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Daiichi Pharma/Astra Zeneca. Consultant: Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Daiichi Pharma/Astra Zeneca, Puma, Biothernostics Inc., Phillips, Eli Lilly, Foundation Medicine.

Prof Ronald de Wit, MD, PhD
Prof Ronald de Wit, MD, PhD
Section Lead GU track
Dpt Med One Erasmus MC Cancer Institute
Rotterdam NL

Disclosures: Grant/Research Support: Bayar, Sanofi. Consultant: Bayer, Sanofi, Merck, Astellas.

Luis Paz-Ares Rodriguez, MD
Luis Paz-Ares Rodriguez, MD
Head of Medical Oncology Department
Associate Professor of Medicine
University Hospital 12 de Octubre
Madrid, Spain

Disclosures: Grant/Research Support: BMS,AZ, Pharmamar. Consultant: Roche, Merck, BMS, AZ, Lilly, Pfizer, Pharmamar, Bayer, Abbvie, Amgen, Janssen, GSK, Novartis, Ipsen, Boehring, Takeda, Sanofi, Tesaro, Blueprint, Mirati. Other Support: Founder Altum sequencing, genomica.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By